New drug cocktail aims to tame stubborn IBD

NCT ID NCT07487311

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining guselkumab with JAK inhibitors (upadacitinib or tofacitinib) can help people with inflammatory bowel disease that hasn't improved with other treatments. About 80 participants will receive the drug combination and be monitored for 12 and 52 weeks to see if their symptoms and gut inflammation improve. The goal is to find a new option for those with limited choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: guselkumab and JAK inhibitors (upadacitinib or tofacitinib)
What this could lead to: If it works, this combination could offer a new treatment option for people with inflammatory bowel disease that hasn't responded to other therapies.
What could go wrong: This is a small, early-phase study with only 80 participants, so results may not apply to everyone. Combining two strong drugs also raises the risk of side effects like infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMATORY BOWEL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMATORY BOWEL DISEASE

Contacts and locations

Locations

Center of Inflammatory Bowel Disease, Department of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.